Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.
A bacteriophage lambda-based method was used to investigate the development of resistance to protease inhibitors (PI) in one subject infected with human immunodeficiency virus (HIV) type 1 group O who underwent multiple treatment regimens over a period of 4 years. A reduction in the susceptibility to indinavir of 6-fold and a reduction in the susceptibility to saquinavir of 24-fold were recognized after long exposure to these drugs with respect to baseline. The emergence of PI resistance corresponded to the selection of amino acid changes L10V, G48M, F53L, I54V, and L90M at the protease. The results were concordant with those obtained by a drug susceptibility assay with primary HIV isolates.
Rodés
Berta
B
Department of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain.
Poveda
Eva
E
Soriano
Vincent
V
D000328:Adult; D000595:Amino Acid Sequence; D010582:Bacteriophage lambda / Q000187:drug effects / Q000235:genetics; D024882:Drug Resistance, Viral; D005260:Female; D016333:HIV Protease / Q000187:drug effects / Q000235:genetics; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000145:classification / Q000187:drug effects*; D006801:Humans; D019469:Indinavir / Q000494:pharmacology*; D008297:Male; D008826:Microbial Sensitivity Tests / Q000379:methods; D008969:Molecular Sequence Data; D010641:Phenotype; D019258:Saquinavir / Q000494:pharmacology*; D013997:Time Factors
D017320:HIV Protease Inhibitors; D019469:Indinavir; D016333:HIV Protease; D019258:Saquinavir